Insider sells ISRG shares under 10b5-1 plans

Mark Brosius reported sales of ISRG common stock under 10b5-1 plans.

Rhea-AI Filing Summary

Mark Brosius reported sales of ISRG common stock under 10b5-1 plans. The filing lists multiple 10b5-1 sales including 03/04/2026 sales of 431 shares for $213,426.89 and 1,931 shares for $964,456.23, 03/03/2026 sales of 431 shares for $209,974.58 and 217 shares for $106,314.22, 12/15/2025 sale of 464 shares for $254,499.36, and 12/12/2025 sales of 4,500 shares for $2,463,120.00 and 312 shares for $170,776.32.

The filing also lists securities to be sold as Performance Stock Units (522, 02/28/2026) and Restricted Stock Units (1,192, 02/10/2026).

Insights

Insider Transactions Analyst

Routine 10b5-1 sales by Mark Brosius; several trades across Dec 2025–Mar 2026.

The filing lists multiple 10b5-1 sales executed by Mark Brosius with discrete trade dates and per-trade proceeds, for example $2,463,120.00 on 12/12/2025 for 4,500 shares. These entries are itemized as executed sales under prearranged plans.

Such filings document reported dispositions rather than changing company fundamentals; cash-flow treatment and any issuer involvement are not detailed in the excerpt. Subsequent SEC filings or trading disclosures would show further activity if additional 10b5-1 trades occur.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Mark Brosius report in the ISRG Form 144?

He reported multiple 10b5-1 sales of ISRG common stock on specific dates. The filing lists trades on 12/12/2025, 12/15/2025, 03/03/2026, and 03/04/2026 with per-trade share counts and proceeds.

How many shares and proceeds are shown for the largest trade?

The largest single trade listed is 4,500 shares for $2,463,120.00. That sale is recorded on 12/12/2025 as a 10b5-1 plan execution in the filing excerpt.

Does the filing show planned awards or other securities to be sold?

Yes; the filing lists 522 Performance Stock Units dated 02/28/2026 and 1,192 Restricted Stock Units dated 02/10/2026. Those line items appear under securities to be sold.

Are these sales labeled as 10b5-1 plan transactions?

Yes; each listed sale is described as a "10b5-1 Sale" for Mark Brosius. The excerpt itemizes each sale date, share count, and gross proceeds for those plan executions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 04:43 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002010300
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	INTUITIVE SURGICAL INC
SEC File Number	000-30713
Address of Issuer	1020 Kifer Road Sunnyvale CALIFORNIA 94086
Phone	4085232100
Name of Person for Whose Account the Securities are To Be Sold	MARK BROSIUS
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1714	859022.52	355130237	03/05/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/28/2026	Performance Stock Units	Issuer			522	02/28/2026	N/A
Common	02/10/2026	Restricted Stock Units	Issuer			1192	02/10/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for MARK BROSIUS 1020 Kifer Road Sunnyvale CA 94086	Common	03/04/2026	431	213426.89
10b5-1 Sales for MARK BROSIUS 1020 Kifer Road Sunnyvale CA 94086	Common	03/04/2026	1931	964456.23
10b5-1 Sales for MARK BROSIUS 1020 Kifer Road Sunnyvale CA 94086	Common	03/03/2026	431	209974.58
10b5-1 Sales for MARK BROSIUS 1020 Kifer Road Sunnyvale CA 94086	Common	03/03/2026	217	106314.22
10b5-1 Sales for MARK BROSIUS 1020 Kifer Road Sunnyvale CA 94086	Common	12/15/2025	464	254499.36
10b5-1 Sales for MARK BROSIUS 1020 Kifer Road Sunnyvale CA 94086	Common	12/12/2025	4500	2463120.00
10b5-1 Sales for MARK BROSIUS 1020 Kifer Road Sunnyvale CA 94086	Common	12/12/2025	312	170776.32

144: Remarks and Signature

Remarks
Date of Notice	03/05/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/12/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Mark Brosius
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)